Last reviewed · How we verify
subcutaneous heparin anticoagulation
At a glance
| Generic name | subcutaneous heparin anticoagulation |
|---|---|
| Also known as | systemic intravenous anticoagulation as SOC |
| Sponsor | Baylor Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study (PHASE4)
- Anticoagulation-free VV ECMO for Acute Respiratory Failure (PHASE2, PHASE3)
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT） (PHASE4)
- The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients. (PHASE2)
- Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (PHASE4)
- Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- subcutaneous heparin anticoagulation CI brief — competitive landscape report
- subcutaneous heparin anticoagulation updates RSS · CI watch RSS
- Baylor Research Institute portfolio CI